To compare the efficacy of an investigational therapy when combined with standard therapy versus standard therapy alone, when looking at progression-free survival.
To describe current and evolving patterns for diagnosis, treatment, clinical monitoring and outcome measures in patients with low-risk or high-risk MDS, MDS risk not determined, and AML. To compare routine clinical practice patterns with existing management guidelines. To describe treatment patterns & outcomes in patients with cytogenetic abnormalities. To summarize patient-reported outcomes, economic outcomes, and their association with patient characteristics, treatment regimens, and clinical outcomes.
To estimate the relationship between chemotherapy & survival
To describe the clinical burden, healthcare resource utilization, complications, practice patterns, and therapy strategies in patients treated for PV in academic & community clinical practices within the United States.
This is a 6 month extension study to evaluate the safety of long-term Sativex® therapy when used as an adjunctive measure in patients with advanced cancer.
To assess the efficacy and safety of iron chelation therapy with a single agent compared to placebo in patients with myelodysplastic syndromes (MDS) (low/int-1 risk) and transfusional iron overload.
This nine week study will aim to determine the efficacy, safety and tolerability of Sativex® as an adjunctive treatment, compared with placebo in relieving uncontrolled persistent chronic pain in patients with advance cancer.
o Treat pain in patients with advanced cancer that experience inadequate pain relief with currently available medications or have side effects with currently available medications.
To compare the efficacy of 2 different treatments in patients with Chronic Phase CML as measured by major molecular response (MMR) rate at 12 months.
To test the safety & effectiveness of an investigational compound to determine if weekly doses can be safely administered to reduce the incidence (occurrence of), duration (length of time) and severity (amount of pain) of oral mucositis (painful sores in the mouth) in patients with advanced head & neck cancer receiving radiation and chemotherapy.
To test two different dose levels in patients with squamous cell carcinoma of the head and neck who will receive treatment with chemotherapy & radiation therapy and may develop oral Mucositis as a result of the Chemoradiation therapy.
To better understand the clinical effectiveness of therapies used in treating relapsed/refractory multiple myeloma (MM) in the real-world clinical practice.
To compare progression-free survival, overall response between two single-agent therapies in patients with indolent NHL that has relapsed.
To determine factors associated with prophylactic pegfilgrastim administration from the community oncology setting.
To compare the oncologic outcomes (local control, regional control, distant control, disease-free survival, cause-specific survival, overall survival) and rate of toxicities (frequency of symptoms) for patients diagnosed with a cancer in the chest or female reproductive tract.
To compare the effects of performing a standard lymph node removal versus an extended lymph node removal.
To demonstrate the overall survival of subjects receiving a single agent for Chemo-Induced Anemia in Stage IV Non-small Cell Lung Cancer patients.